TQB2868 + anlotinib

**TQB2868 + anlotinib** is an experimental drug combination under investigation primarily for the first-line treatment of metastatic pancreatic neoplasms. TQB2868 is an investigational monoclonal antibody whose precise target has not been published in available clinical trial records. Anlotinib is a small molecule oral multitargeted tyrosine kinase inhibitor (TKI) that inhibits angiogenesis and tumor proliferation by targeting receptors such as vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and fibroblast growth factor receptor 1 (FGFR1), with downstream inhibition of ERK signal transduction. The combination is designed to leverage immune modulation (TQB2868) with antiangiogenic and antiproliferative effects (anlotinib), in combination with chemotherapy (gemcitabine and albumin-bound paclitaxel) for enhanced efficacy against pancreatic tumors[1][2][3][5].

Brand names

TQB2868 + anlotinib

Other names

TQB2868 and anlotinibTQB-2868 and anlotinibTQB 2868 and anlotinibTQB2868 injection plus anlotinib capsuleTQB-2868 injection plus anlotinib capsuleTQB 2868 injection plus anlotinib capsule